Kwangdong Pharmaceutical KRX:009290KOSPI

광동제약 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days33
DART filings, 7 days0
Articles tracked258since Sep 11

In Q2 2026, Kwangdong Pharmaceutical reported revenue of ₩440bn, up 3.4% year on year, and operating profit of ₩2.8bn. Kwangdong Pharmaceutical (광동제약) appeared in 33 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 30 articles. The most common catalyst was risk & warnings (1). It was most often mentioned alongside Daewoong Pharma, Hanmi Science and Daewon Pharmaceutical.

Filing signals Major holder adding Screener

Kwangdong Pharmaceutical quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩440bn+3.4%₩2.8bn
margin 0.6%
₩3.2bn
Q1 2026₩411bn+8.8%₩7.5bn
margin 1.8%
₩4.9bn
Q4 2025 derived₩412bn+5.4%₩12.3bn
margin 3.0%
₩3.8bn
Q3 2025₩445bn+4.7%₩10.9bn
margin 2.4%
₩11.1bn
Q2 2025₩425bn+3.0%₩4.5bn
margin 1.1%
₩2.4bn
Q1 2025₩378bn-8.5%₩3.3bn
margin 0.9%
₩4.1bn
Q4 2024 derived₩391bn+1.7%₩6.7bn
margin 1.7%
₩12.8bn
Q3 2024₩425bn+6.7%₩1.4bn
margin 0.3%
₩9.0bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Kwangdong Pharmaceutical top stories 2 weeks, by number of outlets

  1. 1
    광동제약 AI센터, 산기협 기업부설연구소 인정
    14 outlets · 14 articlesFirst report Oct 26 07:58 메디포뉴스
  2. 2
  3. 3
    광동제약 창립 63주년…최성원 회장 "내실경영·사회적 책임 강화"
    9 outlets · 9 articlesFirst report Oct 19 08:40 메디파나뉴스
  4. 4
    광동제약, 예술로 전하는 환경의 가치…'잊혀지지 않는 展' 개최
    5 outlets · 5 articlesFirst report Oct 22 08:04 메디파나뉴스
  5. 5
    광동제약 AI센터, 기업부설연구소 인정…전사 AI 과제 통합 관리
    3 outlets · 3 articlesFirst report Oct 26 08:02 메디파나뉴스
  6. 6
    광동제약, 과천 본사서 ‘잊혀지지 않는 展’ 개최
    3 outlets · 3 articlesFirst report Oct 22 08:02 메디포뉴스

Latest Kwangdong Pharmaceutical news Korean headlines